Pay in 4 interest-free payments of $7.11 Learn more
Ships within 48 hours · Estimated delivery Aug 21 - Aug 26
Handling: Allow frozen vials to reach room temperature before opening to minimize condensation
doi: 10.1001/jamapediatrics.2013.1045 23 IdornTKnopFKJrgensenMBChristensenMHolstJJHornumMet al
It demonstrates higher potency at the GIP receptor (EC50: 0.0643 nM) relative to the GLP-1 (EC50: 0.775 nM) and glucagon (EC50: 5.79 nM) receptors (Li et al., 2024)
At the higher doses, results were very consistent: All participants lost at least 5% of their body weight Around 3 in 4 lost 15% or more With placebo, only around 1 in 4 lost 5% or more Phase 3 update (TRIUMPH-4, 68 weeks, topline results) In December 2025 , Eli Lilly shared early (topline) results from a larger phase 3 study (TRIUMPH-4)
US$ 27.45
US$ 27.74
US$ 27.19
